Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-37701
Volltext verfügbar? / Dokumentlieferung
Titel: The prognostic impact of Claudin 6 in papillary renal cell carcinoma
VerfasserIn: Mikuteit, Marie
Zschäbitz, Stefanie
Stöhr, Christine
Herrmann, Edwin
Polifka, Iris
Agaimy, Abbas
Trojan, Lutz
Ströbel, Philipp
Becker, Frank
Wülfing, Christian
Barth, Peter
Stöckle, Michael
Staehler, Michael
Stief, Christian
Haferkamp, Axel
Hohenfellner, Markus
Macher-Göppinger, Stephan
Wullich, Bernd
Noldus, Joachim
Brenner, Walburgis
Roos, Frederik C.
Walter, Bernhard
Otto, Wolfgang
Burger, Maximilian
Schrader, Andres Jan
Hartmann, Arndt
Steffens, Sandra
Erlmeier, Franziska
Sprache: Englisch
Titel: Pathology - Research and Practice
Bandnummer: 231
Verlag/Plattform: Elsevier
Erscheinungsjahr: 2022
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Background Claudins are promising biomarkers for diagnosis and prognosis or targets for treatment. They play a major role in signal transduction and are important in nearly all aspects of tumorigenesis. Claudin 6 is a member of the claudin family and is part of the tight junction molecule. It is reactivated in several cancer types and serves as prognostic marker in, for example, gastric, breast or non small cell lung cancer. The prognostic role of Claudin 6 in renal cell carcinoma (RCC), especially in papillary RCC (pRCC), is still unclear. Patients and Methods The patients’ sample collection was a joint collaboration of the PANZAR consortium. Patients’ medical history and tumor specimens were collected from n = 240 and n = 128 patients with type 1 and 2 pRCC, respectively. Expression of Claudin 6 was determined by immunohistochemistry. Results In total, Claudin 6 staining was positive in 55 of 240 type 1 and 30 of 128 type 2 pRCC cases. Kaplan-Meier analysis disclosed an overall survival of 84% for Claudin 6- compared to 78% for Claudin 6 + in pRCC type 1 tumors (p = 0.449, log-rank) and 68% for Claudin 6- compared to 65.4% for Claudin 6 + in pRCC type 2 tumors (p = 0.364, log-rank). Conclusion In this study, claudin 6 expression showed no significant association regarding overall survival (OS) and therefore did not qualify as a prognostic marker in pRCC. Future studies will have to determine, whether Claudin 6 plays a prognostic role in other RCC entities. In addition, the function of Claudin 6 as a predictive marker for therapeutic approaches has to be evaluated in future studies.
DOI der Erstveröffentlichung: 10.1016/j.prp.2022.153802
URL der Erstveröffentlichung: https://www.sciencedirect.com/science/article/abs/pii/S0344033822000450
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-377018
hdl:20.500.11880/34104
http://dx.doi.org/10.22028/D291-37701
ISSN: 0344-0338
Datum des Eintrags: 25-Okt-2022
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Urologie und Kinderurologie
Professur: M - Prof. Dr. Michael Stöckle
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Es gibt keine Dateien zu dieser Ressource.


Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt.